Summary
Changes a law to stop U.S. money and ideas from helping China's biotech industry, which could be a risk to national security.
What problem does this solve?
China is using American money and ideas to build up its own medicine and science companies, which could make the U.S. depend on them for important health products. This bill adds biotechnology to a list of protected technologies, which will help stop U.S. investments from going to Chinese biotech companies.
What does this bill do?
Adds biotechnology to restricted technology lists
Updates the Defense Production Act of 1950 to include biotechnology, such as drug development and manufacturing, as a sector where U.S. investment in certain foreign countries is restricted or must be reported.
Requires new rules for biotechnology
Directs the Secretary of the Treasury to create rules within one year to clearly define 'biotechnology' for these investment restrictions, in consultation with other national security and health agencies.
Mandates a national security report
Requires the Secretary of Defense to report to Congress within 60 days on how U.S. investments in China's biotech sector affect national security and military readiness.
Excludes certain biotech areas
Specifies that the new rules for biotechnology must not include agricultural biotech, certain types of industrial fermentation, or basic academic research that is not directly related to medicine.
Who does this affect?
- U.S. biotechnology and pharmaceutical companies
- U.S. investors and venture capital firms
- Chinese biotechnology companies
What is the real world impact?
•
Protects U.S. national security
Prevents U.S. money and knowledge from helping China's biotech industry grow, which could make America dependent on China for important medicines and create security risks.
•
Boosts the U.S. biotech industry
Aims to keep investment and research within the United States by making it harder to send money and ideas to Chinese competitors, potentially helping American companies grow.
•
Could slow down medical progress
Restricting partnerships with Chinese companies might slow down the development of new drugs and medical treatments by limiting global teamwork and access to a large market.
When does this start?
This bill sets several deadlines for government agencies to take action after it becomes law.
Defense Department security report
Within 60 days of the bill becoming law, the Secretary of Defense must submit a report to Congress on the national security risks of U.S. investment in China's biotech sector.
Treasury Department rule creation
No later than 1 year after the bill becomes law, the Secretary of the Treasury must issue a new rule defining 'biotechnology' for investment screening purposes.